Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.

Al-Shawi R, Tennent GA, Millar DJ, Richard-Londt A, Brandner S, Werring DJ, Simons JP, Pepys MB.

Open Biol. 2016 Feb;6(2):150202. doi: 10.1098/rsob.150202.

2.

Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction.

Milde R, Ritter J, Tennent GA, Loesch A, Martinez FO, Gordon S, Pepys MB, Verschoor A, Helming L.

Cell Rep. 2015 Dec 1;13(9):1937-48. doi: 10.1016/j.celrep.2015.10.065. Epub 2015 Nov 25.

3.

Bifunctional crosslinking ligands for transthyretin.

Mangione PP, Deroo S, Ellmerich S, Bellotti V, Kolstoe S, Wood SP, Robinson CV, Smith MD, Tennent GA, Broadbridge RJ, Council CE, Thurston JR, Steadman VA, Vong AK, Swain CJ, Pepys MB, Taylor GW.

Open Biol. 2015 Sep;5(9):150105. doi: 10.1098/rsob.150105.

4.

Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis.

Rowczenio D, Tennent GA, Gilbertson J, Lachmann HJ, Hutt DF, Bybee A, Hawkins PN, Gillmore JD.

Amyloid. 2014 Dec;21(4):276-81. doi: 10.3109/13506129.2014.973105. Epub 2014 Oct 24.

PMID:
25342098
5.

C-reactive protein is essential for innate resistance to pneumococcal infection.

Simons JP, Loeffler JM, Al-Shawi R, Ellmerich S, Hutchinson WL, Tennent GA, Petrie A, Raynes JG, de Souza JB, Lawrence RA, Read KD, Pepys MB.

Immunology. 2014 Jul;142(3):414-20. doi: 10.1111/imm.12266.

6.

Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.

Mangione PP, Porcari R, Gillmore JD, Pucci P, Monti M, Porcari M, Giorgetti S, Marchese L, Raimondi S, Serpell LC, Chen W, Relini A, Marcoux J, Clatworthy IR, Taylor GW, Tennent GA, Robinson CV, Hawkins PN, Stoppini M, Wood SP, Pepys MB, Bellotti V.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1539-44. doi: 10.1073/pnas.1317488111. Epub 2014 Jan 13.

7.

Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.

Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW, Ellmerich S, Mangione PP, Tennent GA, Hutchinson WL, Millar DJ, Bennett G, More J, Evans D, Mistry Y, Poole S, Hawkins PN.

J Immunol Methods. 2012 Oct 31;384(1-2):92-102. doi: 10.1016/j.jim.2012.07.013. Epub 2012 Jul 31.

8.

Trapping of palindromic ligands within native transthyretin prevents amyloid formation.

Kolstoe SE, Mangione PP, Bellotti V, Taylor GW, Tennent GA, Deroo S, Morrison AJ, Cobb AJ, Coyne A, McCammon MG, Warner TD, Mitchell J, Gill R, Smith MD, Ley SV, Robinson CV, Wood SP, Pepys MB.

Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20483-8. doi: 10.1073/pnas.1008255107. Epub 2010 Nov 8.

9.

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB.

Nature. 2010 Nov 4;468(7320):93-7. doi: 10.1038/nature09494. Epub 2010 Oct 20.

10.

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.

Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB.

Br J Haematol. 2010 Mar;148(5):760-7. doi: 10.1111/j.1365-2141.2009.08036.x. Epub 2010 Jan 8.

PMID:
20064157
11.

A common beta-sheet architecture underlies in vitro and in vivo beta2-microglobulin amyloid fibrils.

Jahn TR, Tennent GA, Radford SE.

J Biol Chem. 2008 Jun 20;283(25):17279-86. doi: 10.1074/jbc.M710351200. Epub 2008 Apr 18.

12.

Disease-associated prion protein is not detectable in human systemic amyloid deposits.

Tennent GA, Head MW, Bishop M, Hawkins PN, Will RG, Knight R, Peden AH, McCardle LM, Ironside JW, Pepys MB.

J Pathol. 2007 Dec;213(4):376-83.

PMID:
17955450
13.

Production and characterization of RNA aptamers specific for amyloid fibril epitopes.

Bunka DH, Mantle BJ, Morten IJ, Tennent GA, Radford SE, Stockley PG.

J Biol Chem. 2007 Nov 23;282(47):34500-9. Epub 2007 Sep 18.

14.

Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice.

Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB.

Atherosclerosis. 2008 Jan;196(1):248-55. Epub 2007 Jun 22.

PMID:
17588586
15.

Normal circulating serum amyloid P component concentration in systemic sclerosis.

Tennent GA, Dziadzio M, Triantafillidou E, Davies P, Gallimore JR, Denton CP, Pepys MB.

Arthritis Rheum. 2007 Jun;56(6):2013-7.

16.

Beta-edge interactions in a pentadecameric human antibody V kappa domain.

James LC, Jones PC, McCoy A, Tennent GA, Pepys MB, Famm K, Winter G.

J Mol Biol. 2007 Mar 30;367(3):603-8. Epub 2006 Nov 3.

PMID:
17292396
17.

Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis.

Giorgetti S, Stoppini M, Tennent GA, Relini A, Marchese L, Raimondi S, Monti M, Marini S, Østergaard O, Heegaard NH, Pucci P, Esposito G, Merlini G, Bellotti V.

Protein Sci. 2007 Feb;16(2):343-9.

18.

Is leptin an important physiological regulator of CRP?

Hutchinson WL, Coll AP, Gallimore JR, Tennent GA, Pepys MB.

Nat Med. 2007 Jan;13(1):17-8; author reply 19-21. No abstract available.

PMID:
17206123
19.

Human plasma fibrinogen is synthesized in the liver.

Tennent GA, Brennan SO, Stangou AJ, O'Grady J, Hawkins PN, Pepys MB.

Blood. 2007 Mar 1;109(5):1971-4. Epub 2006 Nov 2.

PMID:
17082318
20.

Organ transplantation in hereditary apolipoprotein AI amyloidosis.

Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J, Tennent GA, Bybee A, Gilbertson J, Rowczenio D, O'Grady J, Heaton ND, Pepys MB, Hawkins PN.

Am J Transplant. 2006 Oct;6(10):2342-7. Epub 2006 Aug 21.

21.

Targeting C-reactive protein for the treatment of cardiovascular disease.

Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP.

Nature. 2006 Apr 27;440(7088):1217-21.

PMID:
16642000
22.

Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome.

Armstrong GD, Mulvey GL, Marcato P, Griener TP, Kahan MC, Tennent GA, Sabin CA, Chart H, Pepys MB.

J Infect Dis. 2006 Apr 15;193(8):1120-4. Epub 2006 Mar 13.

PMID:
16544252
23.

A systematic study of the effect of physiological factors on beta2-microglobulin amyloid formation at neutral pH.

Myers SL, Jones S, Jahn TR, Morten IJ, Tennent GA, Hewitt EW, Radford SE.

Biochemistry. 2006 Feb 21;45(7):2311-21.

PMID:
16475820
24.

Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself.

Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J.

Circ Res. 2005 Nov 25;97(11):e97-103. Epub 2005 Oct 27.

25.

Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.

Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8309-14. Epub 2005 May 26.

26.

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.

Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.

Nature. 2002 May 16;417(6886):254-9.

PMID:
12015594
27.

Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg.

Gillmore JD, Stangou AJ, Tennent GA, Booth DR, O'Grady J, Rela M, Heaton ND, Wall CA, Keogh JA, Hawkins PN.

Transplantation. 2001 Apr 15;71(7):986-92.

PMID:
11349736
28.

Transthyretin Ile84Thr is associated with familial amyloid polyneuropathy.

Booth DR, Stangou A, Williams RS, Gillmore JD, Tennent GA, Hawkins PN.

Hum Mutat. 2000 Nov;16(5):447. No abstract available.

PMID:
11058909
29.

The protofilament substructure of amyloid fibrils.

Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB, Fraser PE.

J Mol Biol. 2000 Jul 28;300(5):1033-9.

PMID:
10903851
30.

Transthyretin Ile73Val is associated with familial amyloidotic polyneuropathy in a Bangladeshi family. Mutations in brief no. 158. Online.

Booth DR, Gillmore JD, Persey MR, Booth SE, Cafferty KD, Tennent GA, Madhoo S, Cochrane SW, Whitehead TC, Pasvol G, Hawkins PN.

Hum Mutat. 1998;12(2):135.

PMID:
10694917
31.

Isolation and characterization of amyloid fibrils from tissue.

Tennent GA.

Methods Enzymol. 1999;309:26-47.

PMID:
10507014
32.

Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity.

Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, Mitchell DA, Cook HT, Butler PJ, Walport MJ, Pepys MB.

Nat Med. 1999 Jun;5(6):694-7.

PMID:
10371509
33.

Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I.

Persey MR, Booth DR, Booth SE, van Zyl-Smit R, Adams BK, Fattaar AB, Tennent GA, Hawkins PN, Pepys MB.

Kidney Int. 1998 Feb;53(2):276-81.

34.

Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene.

Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB.

Nat Med. 1997 Aug;3(8):855-9.

PMID:
9256275
35.

Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.

Booth DR, Tan SY, Booth SE, Tennent GA, Hutchinson WL, Hsuan JJ, Totty NF, Truong O, Soutar AK, Hawkins PN, Bruguera M, Caballería J, Solé M, Campistol JM, Pepys MB.

J Clin Invest. 1996 Jun 15;97(12):2714-21.

36.

Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.

Pepys MB, Tennent GA, Booth DR, Bellotti V, Lovat LB, Tan SY, Persey MR, Hutchinson WL, Booth SE, Madhoo S, Soutar AK, Hawkins PN, Van Zyl-Smit R, Campistol JM, Fraser PE, Radford SE, Robinson CV, Sunde M, Serpell LC, Blake CC.

Ciba Found Symp. 1996;199:73-81; discussion 81-9.

PMID:
8915605
37.

A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis.

Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguyen O, Hutton T, Vigushin DM, Tennent GA, Hutchinson WL, et al.

QJM. 1995 Oct;88(10):695-702. Review.

PMID:
7493166
38.

Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Tennent GA, Lovat LB, Pepys MB.

Proc Natl Acad Sci U S A. 1995 May 9;92(10):4299-303.

40.

Rapid automated enzyme immunoassay of serum amyloid A.

Wilkins J, Gallimore JR, Tennent GA, Hawkins PN, Limburg PC, van Rijswijk MH, Moore EG, Pepys MB.

Clin Chem. 1994 Jul;40(7 Pt 1):1284-90.

41.

Glycobiology of the pentraxins.

Tennent GA, Pepys MB.

Biochem Soc Trans. 1994 Feb;22(1):74-9. Review. No abstract available.

PMID:
8206305
42.

Studies of the structure and binding properties of hamster female protein.

Tennent GA, Baltz ML, Osborn GD, Butler PJ, Noble GE, Hawkins PN, Pepys MB.

Immunology. 1993 Dec;80(4):645-51.

43.

Molecular characterization of Limulus polyphemus C-reactive protein. II. Asparagine-linked oligosaccharides.

Amatayakul-Chantler S, Dwek RA, Tennent GA, Pepys MB, Rademacher TW.

Eur J Biochem. 1993 May 15;214(1):99-110.

44.

Molecular characterization of Limulus polyphemus C-reactive protein. I. Subunit composition.

Tennent GA, Butler PJ, Hutton T, Woolfitt AR, Harvey DJ, Rademacher TW, Pepys MB.

Eur J Biochem. 1993 May 15;214(1):91-7.

45.

Human lysozyme gene mutations cause hereditary systemic amyloidosis.

Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CC, Terry CJ, et al.

Nature. 1993 Apr 8;362(6420):553-7.

PMID:
8464497
46.

The International Standard for Thyroxine Binding Globulin.

Bristow AF, Gaines-Das RE, Buttress N, Gallimore JR, Tennent GA, Pepys MB.

Clin Endocrinol (Oxf). 1993 Apr;38(4):361-6.

PMID:
8319367
47.

Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis.

Soutar AK, Hawkins PN, Vigushin DM, Tennent GA, Booth SE, Hutton T, Nguyen O, Totty NF, Feest TG, Hsuan JJ, et al.

Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7389-93.

48.

Serum amyloid P component in chronic renal failure and dialysis.

Nelson SR, Tennent GA, Sethi D, Gower PE, Ballardie FW, Amatayakul-Chantler S, Pepys MB.

Clin Chim Acta. 1991 Aug 30;200(2-3):191-9.

PMID:
1777968
49.

Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.

Hawkins PN, Tennent GA, Woo P, Pepys MB.

Clin Exp Immunol. 1991 May;84(2):308-16.

50.

Plasma leucocyte elastase concentrations in smokers.

Hind CR, Joyce H, Tennent GA, Pepys MB, Pride NB.

J Clin Pathol. 1991 Mar;44(3):232-5.

Supplemental Content

Loading ...
Support Center